【摘要】 乙型肝炎的治愈是医生和患者共同追求的目标,近年来在临床也越来越受到重视。达到临床治愈的患者,可显著降低肝硬化和肝癌的风险,同时降低患者的死亡率。目前批准用于慢性乙型肝炎抗病毒治疗的药物主要有2类,即干扰素类和核苷(酸)类似物,但大多数患者仍不能达到临床治愈。面对当前治疗现状,根据乙型肝炎病毒的生命周期、针对不同靶点开发乙型肝炎新药具有重要意义。综述慢性乙型肝炎抗病毒治疗新药研究进展。更多还原

【Abstract】 In recent years, while hepatitis B has drawn more and more attention in clinic practice, its cure is a common goal for all the patients and their doctors. The risk of cirrhosis and liver cancer as well as mortality are significantly reduced in patients who achieve clinical cure. Currently, there are two main types of drugs approved for antiviral treatment of chronic hepatitis B: interferons(IFNs) and nucleos(t)ide analogs, which still can’t lead to clinical cure in most cases. In consideration of current treatment status, it is of great significance to develop new antihepatitis B drugs against different targets in the life cycle of HBV. This paper reviewed the research progress in new drugs for antiviral treatment of chronic hepatitis B.更多还原